A number of companies are developing minimally invasive devices that produce the weight-reducing effects of a gastric bypass minus the actual surgery.
VIVUS’ Qnexa Shows Promise For Diabetics
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
